FDA Proposes Registry On Thermal Ablation For Breast Cancer
This article was originally published in The Gray Sheet
Executive Summary
FDA says the development of a patient registry might help industry design better early-stage clinical trials for evaluating ablation as an alternative breast tumor treatment to more invasive surgery
You may also be interested in...
Consensus Elusive On Design Of Breast Cancer Ablation Registry
Cost and patient participation will probably be major impediments in developing a registry of breast cancer ablation clinical trials, according to stakeholder comments to FDA
Consensus Elusive On Design Of Breast Cancer Ablation Registry
Cost and patient participation will probably be major impediments in developing a registry of breast cancer ablation clinical trials, according to stakeholder comments to FDA
FDA Workshop Weighs Breast Cancer Ablation Benefits, Trial Protocol Issues
Stakeholders debating appropriate feasibility study protocol for image-guided thermal ablation of early-stage breast cancer are cautioning that increased use of advanced imaging for the procedures may counter some of the anticipated cost benefits